15 February 2012
Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM-L, Siderowf AD, Hurtig H, LItvan I, Schiess MC, Peskind EF, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J
Phosphorylated α-synuclein (PS-129), a protein implicated in the
pathogenesis of Parkinson’s disease (PD), was identified
by mass spectrometry in human cerebrospinal
fluid (CSF).
A highly sensitive and specific assay was established and
used to
measure PS-129 together with total α-synuclein
in the CSF of patients with PD, other parkinsonian disorders such as
multiple
system atrophy (MSA) and progressive
supranuclear palsy (PSP), and healthy individuals (a total of ~600
samples).
PS-129 CSF
concentrations correlated weakly with PD
severity and, when combined with total α-synuclein concentrations in
CSF, contributed
to distinguishing PD from MSA and PSP. Further
rigorous validation in independent cohorts of patients, especially those
where
samples have been collected longitudinally, will
determine whether the concentration of PS-129 in CSF will be useful for
diagnosing
PD and for monitoring PD severity and
progression.
